CULLINAN THERAPEUTICS, INC. Net Income (Loss) Attributable to Noncontrolling Interest
CULLINAN THERAPEUTICS, INC. (CGEM) reported Net Income (Loss) Attributable to Noncontrolling Interest of $0 for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-10.
Financial Statements › Income Statement › Net Income
us-gaap:NetIncomeLossAttributableToNoncontrollingInterest · last filed 2026-03-10
- CULLINAN THERAPEUTICS, INC. net income (loss) attributable to noncontrolling interest for the quarter ending 2025-12-31 was $0.00.
- CULLINAN THERAPEUTICS, INC. net income (loss) attributable to noncontrolling interest for the quarter ending 2025-09-30 was $0.00.
- CULLINAN THERAPEUTICS, INC. net income (loss) attributable to noncontrolling interest for the quarter ending 2025-06-30 was $0.00.
- CULLINAN THERAPEUTICS, INC. net income (loss) attributable to noncontrolling interest for the quarter ending 2025-03-31 was $0.00.
- CULLINAN THERAPEUTICS, INC. net income (loss) attributable to noncontrolling interest for fiscal 2025 was $0.00.
- CULLINAN THERAPEUTICS, INC. net income (loss) attributable to noncontrolling interest for fiscal 2024 was -$192.00K.
- CULLINAN THERAPEUTICS, INC. net income (loss) attributable to noncontrolling interest for fiscal 2023 was -$1.94M.
- CULLINAN THERAPEUTICS, INC. net income (loss) attributable to noncontrolling interest for fiscal 2022 was -$2.02M.
| Period end | Net Income (Loss) Attributable to Noncontrolling Interest 3 month | Net Income (Loss) Attributable to Noncontrolling Interest 6 month | Net Income (Loss) Attributable to Noncontrolling Interest 9 month | Net Income (Loss) Attributable to Noncontrolling Interest 12 month |
|---|---|---|---|---|
| 2025-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-10 | $0.00 derived: sum of 2 quarters · filed 2026-03-10 | $0.00 derived: sum of 3 quarters · filed 2026-03-10 | $0.00 10-K · filed 2026-03-10 |
| 2025-09-30 | $0.00 10-Q · filed 2025-11-06 | $0.00 derived: sum of 2 quarters · filed 2025-11-06 | $0.00 10-Q · filed 2025-11-06 | $0.00 derived: sum of 4 quarters · filed 2026-03-10 |
| 2025-06-30 | $0.00 10-Q · filed 2025-08-07 | $0.00 10-Q · filed 2025-08-07 | $0.00 derived: sum of 3 quarters · filed 2026-03-10 | $0.00 derived: sum of 4 quarters · filed 2026-03-10 |
| 2025-03-31 | $0.00 10-Q · filed 2025-05-08 | $0.00 derived: sum of 2 quarters · filed 2026-03-10 | $0.00 derived: sum of 3 quarters · filed 2026-03-10 | $0.00 derived: sum of 4 quarters · filed 2026-03-10 |
| 2024-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-10 | $0.00 derived: sum of 2 quarters · filed 2026-03-10 | $0.00 derived: sum of 3 quarters · filed 2026-03-10 | -$192.00K 10-K · filed 2026-03-10 |
| 2024-09-30 | $0.00 10-Q · filed 2025-11-06 | $0.00 derived: sum of 2 quarters · filed 2025-11-06 | -$192.00K 10-Q · filed 2025-11-06 | -$1.95M derived: sum of 4 quarters · filed 2025-11-06 |
| 2024-06-30 | $0.00 10-Q · filed 2025-08-07 | -$192.00K 10-Q · filed 2025-08-07 | -$1.95M derived: sum of 3 quarters · filed 2025-08-07 | -$1.95M derived: sum of 4 quarters · filed 2025-08-07 |
| 2024-03-31 | -$192.00K 10-Q · filed 2025-05-08 | -$1.95M derived: sum of 2 quarters · filed 2025-05-08 | -$1.95M derived: sum of 3 quarters · filed 2025-05-08 | -$1.95M derived: sum of 4 quarters · filed 2025-05-08 |
| 2023-12-31 | -$1.76M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-27 | -$1.76M derived: sum of 2 quarters · filed 2025-02-27 | -$1.76M derived: sum of 3 quarters · filed 2025-02-27 | -$1.94M 10-K · filed 2025-02-27 |
| 2023-09-30 | $0.00 10-Q · filed 2024-11-07 | $0.00 derived: sum of 2 quarters · filed 2024-11-07 | -$179.00K 10-Q · filed 2024-11-07 | -$485.00K derived: sum of 4 quarters · filed 2024-11-07 |
| 2023-06-30 | $0.00 10-Q · filed 2024-08-08 | -$179.00K 10-Q · filed 2024-08-08 | -$485.00K derived: sum of 3 quarters · filed 2024-08-08 | -$571.00K derived: sum of 4 quarters · filed 2024-08-08 |
| 2023-03-31 | -$179.00K 10-Q · filed 2024-05-15 | -$485.00K derived: sum of 2 quarters · filed 2024-05-15 | -$571.00K derived: sum of 3 quarters · filed 2024-05-15 | -$1.40M derived: sum of 4 quarters · filed 2024-05-15 |
| 2022-12-31 | -$306.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-14 | -$392.00K derived: sum of 2 quarters · filed 2024-03-14 | -$1.23M derived: sum of 3 quarters · filed 2024-03-14 | -$2.02M 10-K · filed 2024-03-14 |
| 2022-09-30 | -$86.00K 10-Q · filed 2023-11-08 | -$919.00K derived: sum of 2 quarters · filed 2023-11-08 | -$1.71M 10-Q · filed 2023-11-08 | -$3.40M derived: sum of 4 quarters · filed 2023-11-08 |
| 2022-06-30 | -$833.00K 10-Q · filed 2023-08-10 | -$1.63M 10-Q · filed 2023-08-10 | -$3.32M derived: sum of 3 quarters · filed 2023-08-10 | -$4.23M derived: sum of 4 quarters · filed 2023-08-10 |
| 2022-03-31 | -$794.00K 10-Q · filed 2023-05-11 | -$2.49M derived: sum of 2 quarters · filed 2023-05-11 | -$3.40M derived: sum of 3 quarters · filed 2023-05-11 | -$4.20M derived: sum of 4 quarters · filed 2023-05-11 |
| 2021-12-31 | -$1.69M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-09 | -$2.60M derived: sum of 2 quarters · filed 2023-03-09 | -$3.40M derived: sum of 3 quarters · filed 2023-03-09 | -$1.92M 10-K · filed 2023-03-09 |
| 2021-09-30 | -$909.00K 10-Q · filed 2022-11-14 | -$1.71M derived: sum of 2 quarters · filed 2022-11-14 | -$223.00K 10-Q · filed 2022-11-14 | -$983.00K derived: sum of 4 quarters · filed 2022-11-14 |
| 2021-06-30 | -$803.00K 10-Q · filed 2022-08-10 | $686.00K 10-Q · filed 2022-08-10 | -$74.00K derived: sum of 3 quarters · filed 2022-08-10 | -$1.53M derived: sum of 4 quarters · filed 2022-08-10 |
| 2021-03-31 | $1.49M 10-Q · filed 2022-05-16 | $729.00K derived: sum of 2 quarters · filed 2022-05-16 | -$727.00K derived: sum of 3 quarters · filed 2022-05-16 | -$5.98M derived: sum of 4 quarters · filed 2022-05-16 |
| 2020-12-31 | -$760.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-17 | -$2.22M derived: sum of 2 quarters · filed 2022-03-17 | -$7.47M derived: sum of 3 quarters · filed 2022-03-17 | -$7.66M 10-K · filed 2022-03-17 |
| 2020-09-30 | -$1.46M 10-Q · filed 2021-11-09 | -$6.71M derived: sum of 2 quarters · filed 2021-11-09 | -$6.90M 10-Q · filed 2021-11-09 | |
| 2020-06-30 | -$5.25M 10-Q · filed 2021-08-10 | -$5.44M 10-Q · filed 2021-08-10 | ||
| 2020-03-31 | -$190.00K 10-Q · filed 2021-05-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Monte Rosa Therapeutics, Inc. (GLUE) | United States | $1.002B | -12.81 |
| Odyssey Therapeutics, Inc. (ODTX) | United States | $0.960B | |
| MeiraGTx Holdings plc (MGTX) | United States | $1.061B | 16.10 |
| Vor Biopharma Inc. (VOR) | United States | $1.091B | 1.60 |
| Sana Biotechnology, Inc. (SANA) | United States | $0.886B | -4.92 |
| Candel Therapeutics, Inc. (CADL) | United States | $0.885B | -8.86 |
| Attovia Therapeutics, Inc. (ATTO) | United States | $0.828B | |
| Solid Biosciences Inc. (SLDB) | United States | $0.802B | -5.07 |
| Replimune Group, Inc. (REPL) | United States | $1.186B | -3.13 |
| 4D Molecular Therapeutics, Inc. (FDMT) | United States | $0.733B | -4.10 |